Summit Therapeutics jumps as ELCC 2026 spotlights new ivonescimab brain-metastases data
Summit Therapeutics shares rose after the company highlighted new Phase III ivonescimab data being presented at ELCC 2026, including improved intracranial progression-free survival in EGFR-mutated NSCLC patients with baseline brain metastases. The update keeps focus on ivonescimab’s late-stage profile ahead of its targeted November 14, 2026 FDA action date.
1. What’s moving the stock today
Summit Therapeutics (SMMT) is trading higher as investors react to fresh visibility on ivonescimab data being featured at the 2026 European Lung Cancer Congress (ELCC) in Copenhagen. The company’s March 27, 2026 announcement outlined multiple Phase III data sets in advanced NSCLC, including a poster focused on intracranial efficacy in the global Phase III HARMONi study, which is a key clinical battleground in EGFR-mutated disease where brain metastases are common. (smmttx.com)
2. The key data point investors are keying on
The intracranial poster centers on outcomes in patients with and without asymptomatic brain metastases at baseline in HARMONi. Posted headline figures circulating from the ELCC materials highlight longer intracranial progression-free survival for ivonescimab plus chemotherapy versus chemotherapy alone in patients with baseline brain metastases (10.1 months vs 6.5 months; hazard ratio 0.53; nominal p=0.0068). (stocktitan.net)
3. Why it matters from here
For SMMT, incremental evidence of activity in the central nervous system can be valuation-relevant because it speaks to differentiation versus standard approaches in a population where controlling brain disease can drive treatment choice and sequencing. The ELCC update also lands in a timeline where investors are increasingly framing the story around regulatory execution and the pathway to potential commercialization milestones. (smmttx.com)
4. What to watch next
The next major gating item remains the U.S. regulatory clock for ivonescimab, with the application having been accepted and an FDA target action date cited as November 14, 2026. Any subsequent detailed ELCC disclosures, additional Phase III updates across the broader HARMONi program, or new combination-trial starts tied to recent collaboration announcements could create follow-through volatility in either direction. (stockinsights.ai)